Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6780477 | 0.89 | HTR2A (0.55) | HTR2AHTR7DRD2KCNH2OPRM1 | |
| SCHEMBL6774082 | 0.81 | TACR2 (0.56) | HTR2ADRD2KCNH2OPRM1OPRD1 | |
| SCHEMBL7539756 | 0.77 | ADRA1D (0.66) | — | |
| SCHEMBL6778865 | 0.77 | TACR2 (0.55) | DRD2OPRM1OPRD1CYP1A2CYP3A4 | |
| SCHEMBL6779973 | 0.77 | OPRM1 (0.59) | HTR2ADRD2KCNH2OPRM1OPRD1 | |
| SCHEMBL6779960 | 0.76 | CYP3A4 (0.51) | OPRM1OPRD1CYP3A4CCR5OPRK1 | |
| SCHEMBL6775075 | 0.76 | TACR2 (0.49) | OPRM1OPRD1CCR5 | |
| SCHEMBL6780476 | 0.76 | KCNA3 (0.52) | OPRM1OPRD1CYP1A2CYP3A4 | |
| SCHEMBL6780052 | 0.76 | CCR5 (0.62) | OPRM1OPRD1CCR5OPRK1 | |
| SCHEMBL6780806 | 0.75 | HSD11B1 (0.57) | DRD2KCNH2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790854-B2 | TREATMENT OF DEPRESSION, EPILEPSY AND PARKINSON'S ISEASE, ANALGESICS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1277737-A1 | DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRL1 | HTR2A 265/4885HTR7 189/4885DRD2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.